Method of production of polyfunctional magnetic nanoparticles based on magnetosomes of bacterial origin

FIELD: biotechnology.

SUBSTANCE: as the present invention the method for production of polyfunctional magnetic nanoparticles based on bacterial magnetosomes and the hybrid protein MGG is provided, which enables to obtain magnetosomes binding immunoglobulins of the IgG class on the fragment Fc. The result is achieved in that in the lipid membrane of bacterial magnetosomes by ultrasonic treatment the hybrid protein MGG is integrated, which amino acid sequence comprises the transmembrane domain and the binding area of immunoglobulins.

EFFECT: obtaining polyfunctional magnetic sorbent bearing on the surface of magnetic nanoparticles of ligand, that enable to connect to the particles the immunoglobulins of IgG class.

4 dwg


The invention relates to the field of biotechnology, in particular to biotechnology bacteria, and due to receipt of multifunctional magnetic nanoparticles.

As the present invention, a method for embedding the immunoglobulin-binding proteins in natural membrane of bacterial magnetic nanoparticles by treatment of a suspension of particles in a solution of the target protein by ultrasound.

The results of the implementation of the present invention can be used in the development of methods for magnetic immunoassay for the detection of target antigens and are modified magnetic particles can be used as a sorption agent for isolation of immunoglobulins.

There is a method of conducting magnetic immunoassay using particles of iron oxide Fe2O3where is the surface modification of particles by chemical cross-linking of the antigen with the surface of the particles with glutaric aldehyde. Patent RU (11) 2290641 (13) C1.

A method of obtaining modified magnetic nanoparticles of bacterial origin, in which the embedding target protein molecules in the membrane of the nanoparticles is carried out by genetic transformation of bacteria producing magnetic nanoparticles vector, which includes the gene encoding in trively protein. Embedding the desired protein into the membrane of magnetic nanoparticles is the result of natural biochemical processes inside living cells (U.S. Patent US 20100292495).

Also known is a method of obtaining modified magnetic nanoparticles of bacterial origin, in which the embedding target protein molecules in the membrane of the nanoparticles is carried out by expression of a hybrid protein MagA/target protein in cells magnetotacticum bacteria CA-1, what is this method similar to the previous (U.S. Patent US 5861285).

A method of obtaining modified magnetic nanoparticles of bacterial origin, which is conducted by chemical cross-linking of antibodies against the target protein (Bt-toxin of the bacterium Bacillus thuringiensis) with the bacterial membrane magnetosome bacteria by the method of carboxymethylate (EU patent CN 1024193 70 (A)).

The disadvantages of the above methods is either insufficient specificity of binding the target substance to the surface of magnetic particles (as is the case with chemical blending) or uncontrolled embedding level of the modifying agent in the membrane magnetosome (case of genetic modification).

The analysis of patent sources shows that despite the continuously increasing flow of information about how to use bacterial magnetic on what acustic (magnetism), there is an urgent need for a relatively simple and effective methods of surface modification of magnetism for the purpose of placement on the outer membrane of the desired target compounds. Obtained by such methods modified magnetosome can be used in the future for research in fundamental science and to solve applied problems - targeted drug delivery, magnetic resonance therapy of diseases, development of methods of magnetic immunoassay diagnostics and so on.

The objective of the proposed method is highly effective embedding of the immunoglobulin-binding proteins in the natural membrane magnetism that allows you to get polyfunctional (due to the possibility of further binding of the built-protein antibodies of different specificity) magnetic nanoparticles based on magnetism of bacterial origin. As the source of magnetism was selected bacterium Magnetospirillum strain SO-1, isolated from coastal sediments ragovka (Kislovodsk). This strain differs from the known cultivated magnetotacticum bacteria increased aerotolerant, high growth rate and sustainable products magnetism in a wide range of culture conditions.

Thus, the invention is a method of obtaining multifunctional magnetic nanoparticles based on magnetosome bacterial origin should:

a) to ensure the integration of the hybrid protein MGG [1] (SEQ ID No. 1) in the bacterial membrane magnetosome the result is ultrazvukovoy processing.

N-end of the hybrid protein (amino acid nos 1-124) contains the sequence of amino acids with hydrophobic properties, the corresponding protein Mam12 membrane magnetosome bacteria Magnetospirillum magnetotacticum MS-1, which provides a consolidation of protein molecules in the lipoprotein membrane bacterial nanoparticles. With the end (amino acid No. 130-284) is a tandemly repeated synthetic analogue of a fragment of the immunoglobulin-binding protein a of Staphylococcus aureus. N - and C-ends of the protein are linked glycine-serine hinge (amino acid No. 125-129)ensuring the independence of the folding of the two domains of the protein;

b) to ensure the binding of the antibody of class IgG for Fc-fragment

The implementation of the invention

Cell lines and culture medium for growth of cells

E. coli strain BL21 (DE3) (F-ompT hsdSB (rB-mB-) gal dcm (DE3)) (Novagene, USA), Magnetospirillum sp.SO-1.

Obtaining and study of the activity of the immunoglobulin-binding protein MGG

The expression of protein MGG held in the cells of E. coli strain BL21 (DE3), transformed with the expression vector pET23a(+)/mGG method autoinduction [2].

Purification of the hybrid protein MGG was performed using metallogenetic affinity chromatography (MOSSES) preparation of membrane fractions of proteins, which is suspended in buffer A (20 mm Tris-HCl, pH 8.0, 500 mm NaCl, 5% glycerol, 10 mm β-mercaptoethanol, 10 mm imidazole, 2 mm PMSF, 15% lauryl sarcosine), and incubated for one hour at room temperature. Solubilizing membrane fraction was applied onto the sorbent Ni-NTA agarose" (Invitrogen, USA), pre-balanced with buffer A. Then carried out the first washing buffer And at least 3 volumes of sorbent), and then buffer A: 20 mm Tris-HCl, pH 8.0, 1 M NaCl, 5% glycerol, 5 mm imidazole, 1% lauryl sarcosine (at least 3 volumes of sorbent). The elution of the target protein was buffer containing 20 mm Tris-HCl, pH 7.5, 130 mm NaCl, 5% glycerol, 500 mm imidazole, 0.5% lauryl sarcosine. The eluate were dialyzed in 20 mm Tris-HCl, pH 7.5 buffer containing 50 mm NaCl, 10% glycerol; 14.6 mm laurylsarcosine over night at +4°C. the Presence of getservletinfo sequence at the C-end of the hybrid proteins has allowed one to obtain highly purified preparation of proteins using MOSSES.

The binding ability of the modified protein antibodies were determined using ELISA. In the wells barbirolli 1 mg of human insulin over night at +4°C. Residual sorption blocked 1.5% solution of BSA in PBST buffer (137 mm NaCl, 2.7 mm KS1, 10 mm Na2HPO4, 1.8 mm KH2PO4, 0.01% NaN3, 0.05% Tween 20) for one hour. Next was added 100 μl (1 μg/ml) monoclonal mouse antibodies against human insulin (Imtek, Russia), and incubated for one hour at room temperature. The wells were washed 4 times with PBST buffer, and then applied with the specified dilutions hybrid of the first protein and incubated at room temperature for 1 h After the same washing for 1 h were incubated with 0.1 µg of mouse antibodies against his-tag tag (Imtek, Russia); system detection - peroxide/peroxidase horseradish, chromogenic substrate TMB (Sigma, USA). As a negative control used a polypeptide carrying the his-tag tag at the C-end.

The specificity of the interaction was determined by calculating the dissociation constant of the complex hybrid protein with the antibody according to [3]. To each well was applied at 1 µg of the hybrid protein. After blocking the surface of the wells was added to the rabbit antibodies to the Fc fragment of mouse immunoglobulin G conjugated with horseradish peroxidase at specified dilutions. To compare the level of nonspecific binding of the antibody protein MGG, a similar image was obtained hybrid protein MZZ, consisting of protein Mat 12 and the two domains Z (widely used in biotechnology synthetic analogues domain of protein A of S. Aureus). It is shown that proteins MGG and MZZ exhibit a high level of specificity of interaction with antibodies: Kaff(MGG)=1.59±0.12 nm Kaff(MZZ)=1.44±0.16 nm. Based on these results, the conclusion is made about the immunoglobulin-binding activity double G domain, not inferior to the previously known double Z domain.

From literature data [4] it is known that the B-domain of protein A of Staphylococcus aureus is able to communicate only with the Fc fragment of them is noglobulins IgG class.

Selection magnetosome from Magnetospirillum strain SO-1

Biomass Magnetospirillum strain SO-1 was obtained from 1.5 l of culture fluid by centrifugation at 10,000 rpm for 10 min. the Precipitated cells (4 g raw biomass) resuspendable in 20 ml of 20 mm HEPES buffer with pH=7.4 with the addition of EDTA (4 mm) and phenylmethylsulfonyl (0.1 mm) to prevent the destruction of membrane proteins by magnetosome cellular proteases. For more effective destruction of bacterial cells was carried out twice, the procedure of freezing and thawing, the resulting suspension. The final destruction of the cells was measured with an ultrasonic disintegrator Sonopuls UW2070 (Bandelin, Germany) with a frequency of 20 kHz for 10 minutes, the Suspension is destroyed cells was transferred into a clean test tube, and the magnetic fraction was collected on a magnetic stand Promega. To get rid of the destroyed remnants of the bacterial cells magnetic nanoparticles twice washed with 20 mm HEPES-buffer pH=7.4 with the addition of 200 mm NaCl, followed by ten-fold flush magnetosome 20 mm HEPES-buffer pH=7.4 magnetic stand Promega.

Check purity and physicochemical properties of bacterial magnetosome

The purity of the drug magnetism and their physicochemical properties were characterized using the methods of atomic force microscopy (AFM) (INTEGRA prima, NT-MDT, Russia) (FIGURE 1). It is established that magnetos is s, isolated from Magnetospirillum strain SO-1, have the same shape, size magnetic crystals ranged from 45 to 60 nm. Data microscopy indicate the presence of intact lipoprotein membrane. The elemental composition is determined using the method of energy dispersive x-ray spectroscopy. It is shown that the crystals magnetosome consist of magnetite (Fe3O4). Thus, the developed method allows to isolate the magnetic nanoparticles of bacteria Magneto spirillum sp.SO-1 with intact membranes required for subsequent modification by magnetism.

Immobilization of protein MGG on the surface of magnetism. The obtained protein MGG immobilizer on the membrane magnetosome using ultrasonic treatment. Embedding of the protein was carried out in the presence of 10 mm of lauroylsarcosinate sodium and 100 mm NaCl. For modification of bacterial nanoparticles, 1 ml (10 mg/ml) drug magnetosome in 20 mm HEPES-buffer pH=7.4 was mixed with 1 ml (5 mg/ml) protein MGG, with 100 μl NaCl and 10 μl of lauroylsarcosinate sodium. Then there was the sound of the mixture using an ultrasonic disintegrator Sonopuls UW2070 (Bandelin, Germany) with a frequency of 10 kHz (0.5 s/0.5 s) for 1 min Polyfunctional bacterial magnetosome collected on a magnetic stand and washed three times 20 mm HEPES-buffer pH=7.4. Embedding the hybrid protein was checked by AFM method (INTEGRA prima, NT-MDT, Rho is this) (FIG. 2) the Functional activity of the modified method proposed by magnetism was examined using magnetic immunoassay. For this purpose, 10 μl (1 MT/ml) of modified bacterial magnetosome was added to 1 ml of mouse antibodies against the Fc fragment of human immunoglobulin conjugated to horseradish peroxidase, with the specified dilutions and incubated for 30 min at room temperature. Then magnetosome washed 5 times on the magnetic stand 1 ml of 20 mm HEPES-buffer, pH=7.4 to get rid of unbound antibodies. The level of binding is determined spectrophotometrically by a color reaction of peroxidase with tetramethylbenzidine (FIGURE 3).

An example of implementation of the proposed method

10 μl (1 mg/ml) polyfunctional bacterial magnetosome was added to 1 ml of mouse antibodies against human insulin with the specified dilutions and incubated for 30 min at room temperature. With the aim of getting rid of unbound antibody magnetosome washed 5 times on the magnetic stand 1 ml of 20 mm HEPES-buffer, pH=7.4. After which was added 1 ml (1 mg/ml) of rabbit antibodies against the Fc fragment of mouse immunoglobulin conjugated with horseradish peroxidase and incubated for 30 minutes After the same washing unbound antibody was added to 100 μl of chromogenic substrate tetramethylbenzidine, the reaction was stopped by 20 ál of 1 M HCl Optical density of the solution was measured on a spectrophotometer at a wavelength of 405 nm (FIG.No. 4). The data obtained indicate that the multifunctional bacterial magnetosome can be used as a magnetic sorbent for conducting ELISA high sensitivity.


1. Dscruggs, Mavzuna, Assersion, Bab. Obtaining and study of the activity of the modified proteins of the membrane magnetosome. // Applied biochemistry and Microbiology.// In printing.

2. Studier F.W. // Protein Expression and Purification. 2005. No. 41. P.207-234.

3. Loomans E.M.G., Roelen A.J.M., Van Damme H.S., Bloemers H.P.J., Gribau T.C.J., Schielen W.J.C. // J. Immunol. Methods. 1995. No. 184. P.207-217.

4. A.Karimi, A., Matsumura, M., Wright, P.E. & Dyson, H.J. //Characterization of monomeric and dimeric In the domain of Staphyloccocal protein A.// J. Peptide Res., 1999, No. 54, P.344±352.

Sequence listing

SEQ ID No. 1, amino acid sequence of the protein MGG


The method of obtaining multifunctional magnetic nanoparticles based on magnetosome obtained from strain SO-1 bacteria Magnetospirillum, including immobilization of the hybrid protein MGG, having amino acid sequence SEQ ID No. 1 (MPFHLAPYLAKSVPGVGVLGALVGGAAALAKNVRLLKEKRITNTEAAIDTGKETVGAGLATALSAVAATAVGGGLVVSLGTALVAGVAAKYAWDRGVDLVEKELNRGKAANGASDEDILRDELAGSGSGDNKFNKGQQNAFYEILHLPNLNEEQRNGLIQSLKDDPSQSANLLAEAKKLNDAQAPKGSGSGDNKFNKGQQNAFYEILHLPNLNEEQRNGLIQSLKDDPSQSANLLAEAKKLNDAQAPKHHHHHH), in the presence of 10 mm of lauroylsarcosinate sodium and 100 mm NaCl on the surface the bacterial magnetosome by ultrasonic impact frequency of 10 kHz (0.5 s/0.5 s) within 1 min


Same patents:

FIELD: biotechnology.

SUBSTANCE: carrier is proposed for targeted delivery of nucleic acids to cells expressing the receptor CXCR4, which consists of a sequence-ligand to the receptor CXCR4 with the amino acid sequence KPVSLSYRSPSRFFESH, the linker part of two molecules of ε-aminohexanoic acid linking the sequence-ligand to the sequence for compaction of nucleic acids, the sequence providing compaction of nucleic acids and the complex output from endosomes CHRRRRRRHC.

EFFECT: invention can be used for targeted delivery of genetic structures into cells with the receptor CXCR4 on the surfaces, such as malignant tumour and stem cells, in order to correct genetic defects, influence on processes of implementation of the genetic information and prevention of diseases.

3 cl, 7 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology, more specifically to a method for introducing an siRNA molecule into the cytosol of a cell, and can be used in medicine. The method involves contacting said cell with an siRNA molecule, a carrier and a photosensiting agent, and irradiating the cell with light of a wavelength effective to activate the photosensitising agent. The carrier comprises a cationic polyamine such as a lipopolyamine in a non-liposomal formulation, branched polyethyleneimine (PEI), a betacyclodextrin amine polymer, a PAMAM dendrimer molecule, and a cationic peptide such as polyarginine or L- or D-arginine copolymers. The method is used to inhibit the target gene expression, to obtain a cell or a cell population containing the siRNA molecules, as well as to treat or to prevent a disease where the inhibition of one or more genes may be effective, including to treat a malignant growth.

EFFECT: invention enables the PCI-mediated site-specific siRNA delivery into the cytosol of a cell.

27 cl, 15 dwg, 1 tbl, 13 ex

FIELD: biotechnologies.

SUBSTANCE: immunostimulatory complex is described, which includes an RNA in the form of a complex with one or more oligonucleotides. Besides, the oligonucleotide has properties of peptide penetrating into a cell (CPP), contains from 8 to 15 amino acid remains and is characterised by the following general formula: (Arg)1(Lys)m(His)n(Orn)o(Xaa)x. At the same time the main number of remains is selected from Arg, Lys, His, Orn.

EFFECT: invention may be used for transfection of a cell, tissue or organism or for modulation, preferably induction or increasing immune response.

16 cl, 22 dwg, 11 ex

FIELD: biotechnology.

SUBSTANCE: method includes processing of plant cells with intact cellular barriers by complex of carrier - carried material consisting of at least one carried polypeptide and/or polynucleotide component connected with the carrier - internalised positively charged peptide (IPCP), and designed for obtaining the transduced cells and propagation of plant cells for cultivation of plant. And these plant cells are somatic cells preliminary treated with agent permeabilising cells, or gametophytes.

EFFECT: invention enables to obtain effectively genetically engineered plants under conditions of intense cellular uptake of the complex of carrier-carried material.

13 cl, 11 dwg, 5 tbl, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of molecular biology and biotechnology and can be used in medicine and in pharmaceutical industry. RNA molecule, capable of target-specific RNA interference, represents double-stranded RNA molecule, 23 nucleotides long, which has 3'-overhang from 1-5 nucleotides. It is obtained by joining two RNA strands and used for obtaining pharmaceutical composition. When introduced into multicellular eukaryotic organism or in a cell of multicellular eukaryotic organism, said RNA molecule ensures promotion of target-specific RNA interference and leads to reduction of target-gene expression level or to target-gene knockout. Method of promoting target-specific RNA interference by means of said RNA molecule is applied for determination or modulation of gene function. Cell, containing endogenic target nucleic acid, RNA molecule, capable of target-specific RNA interference, and exogenic target nucleic acid, is used in analytical procedures.

EFFECT: application of invention ensures target-gene silencing, mediated by target-specific RNA interference.

40 cl, 23 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: method provides contact of said cell with a peptide nucleic acid (PNA) molecule and a photosensitising agent and cell exposure to light at wave length effective to activate the photosensitising agent where said PNA molecule is conjugated with positive peptide. Also, there are described compositions containing such conjugated PNA molecules, the cells produced with the use of the method, and application of the method.

EFFECT: effective cell capture of peptide nucleic acid molecules conjugated with positive peptide.

37 cl, 13 dwg, 9 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology and genetic engineering, namely to a genetically engineered construct pGoatcasGCSF for human granulocyte colony-stimulating factor (GCSF) expression . The offered invention can be used for producing transgenic animals that are human granulocyte colony-stimulating factor producers. It involves creating the genetically engineered construct pGoatcasGCSF of the size 6386 bps, and a specified nucleotide sequence shown in SEQ ID 1. The genetically engineered construct pGoatcasGCSF includes a 5'-regulatory sequence of the goat CSN1S1 asi-casein gene of the size 3387 bps connected with the full-size human GCSF gene of the size 1485 bps, and a 3'-flanking region of the cow gene CSN1S1 of the size 1514 bps.

EFFECT: stable effective level of human GCSF expression in milk of the transgenic animals, eliminated possibility of ectopic transgenic expression.

9 dwg, 2 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to carbosilane dendrimers and synthesis method and use thereof. Disclosed are novel dendrimers, the ends of branches of which include primary, secondary, tertiary and quaternary amino groups, synthesis method thereof, composition based on said dendrimers and versions of using said dendrimers. The disclosed dendrimers may be used to transport anionic molecules in blood, such as nucleic acid molecules, including ODN and RNAi molecules and other anionic medicinal agents with which they can interact, thus protecting them from interaction with proteins in the plasma and/or enhancing their degree of penetration into target cells. The dendrimers can be used to bind anionic molecules with surfaces, and can also be administered as active components for preventing or treating diseases caused by viruses such as HIV or hepatitis C, or prions whose life cycle can be disrupted by dendrimers.

EFFECT: obtaining novel carbosilane dendrimers, having a wide range of application in medicine and which are processable and biocompatible.

172 cl, 35 dwg, 19 tbl, 57 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a novel chemical compound, specifically to rac-N-[2,3-di(tetradecyloxy)prop-1-yl]pyridinium bromide, which can deliver nucleic acids into mammal cells: .

EFFECT: compound has low toxicity and in form of an alcohol solution, the compound can deliver nucleic acids into mammal cells.

1 cl, 5 ex, 4 tbl, 1 dwg

FIELD: medicine, microbiology.

SUBSTANCE: invention concerns biotechnology, in particular genetic engineering. The recombinant plasmid pT7ApckA::loxpcat is designed by cloning of an incomplete pckA-gene in pT7B1ie-vector. The plasmid contains a fragment of a pckA-gene which includes a gene steady against Chloramfenicolum and loxP-sites. By transformation of cells E.coli with a plasmide DNA pT7ApckA::loxpcat strain E.coli FTR2717-producer L-threonine is obtained.

EFFECT: increase of L-threonine output in presence of high concentration of glucose.

2 cl, 3 dwg, 2 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of obtaining mineral silicic water (MSW), intended for application for medical purposes. The method of obtaining includes hydrolysis of tetraethoxysilane in the TEOS mixture: ethanol: water, acidified by HCl. Nanosol is obtained at a temperature of 55-65°C for 1.5 hours with evaporation of ethanol to the volume reduction by 1/3, then, dilution of the obtained nanosol with a physiological solution NaCl is carried out in 2 steps with equal portions of the physiological solution, preliminarily heated to 40-50 in a ratio of volumes of the initial nanosol: physiological solution 1:7 with 15-minute interval. After each dilution a temperature of the solution is kept in the range of 55-65°C.

EFFECT: increase of the compound application efficiency.

1 ex

FIELD: medicine.

SUBSTANCE: what is described is a method for preparing a nanostructured calcium-phosphate coating for medical implants consisting in sputtering a target of stoichiometric hydroxyapatite Ca10(PO4)6(OH)2 in high-frequency magnetron discharge plasma in the argon environment under pressure of 0.1-1 Pa and target power density of 0.1-1 W/cm2 for 15-180 min at a distance from the target to a carrier within the range of 40 to 50 cm, wherein the nanostructure is formed after a coating procedure in the process of the controlled thermal annealing at a temperature of 700-750°C for 15-30 min.

EFFECT: higher post-coating effectiveness of the production process.

4 dwg

FIELD: biotechnology.

SUBSTANCE: invention relates to compositions and polymeric materials for biomedical use, comprising silver nanoparticles (0.0005-0.02 wt %) stabilised by amphiphilic copolymers of maleic acid (0.0008-0.05 wt %), low molecular weight organic amines (0.0002-0.04 wt %) and water. In addition, the said composition may additionally comprise the polymeric structure-forming agent.

EFFECT: introduction to the composition of the polymer structure-forming agent enables to obtain the macroporous structured hydrogel materials having prolonged bactericidal and antifungal action.

3 cl, 2 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a pharmaceutical composition for the delivery of a pharmaceutical agent to a focus of a disease. The composition contains a water-insoluble pharmaceutical agent which is paclitaxel, a pharmaceutically acceptable carrier which is albumin, preferentially human serum albumin. The relation (wt/wt) of albumin to paclitaxel makes 9:1. The pharmaceutical composition contains nanoparticles containing paclitaxel and albumin wherein the nanoparticles have a size of less than 200 nm.

EFFECT: administering the pharmaceutical composition according to the invention provides enhanced characteristics of the delivery of paclitaxel to the site of the disease and reduced adverse side effects.

24 cl, 5 tbl, 51 ex

FIELD: medicine.

SUBSTANCE: what is described is an umbrella device (occluder) with a modified coating layer for the left atrial appendage occlusion. The umbrella device (occluder) with the modified coating layer is made from a titanium nickelide alloy. It has the coating modified layer having a thickness of 80-95 nm which consists of at least two sub-layers: an external sub-layer having a thickness of 20-25 nm contains oxygen, carbon, silicone and titanium in the following ratio, at %: oxygen 25-65, carbon 1-5, silicone 1-10, titanium - the rest; an intermediate sub-layer having a thickness of 60-70 nm contains oxygen, carbon, silicone, titanium and nickel in the following ratio, at %: oxygen 5-30, carbon 1-5, silicone 10-30, nickel 1-50, titanium - the rest, with silicone reaching its maximum concentration at a depth of 30-35 nm from the surface. The modified coating layer of the umbrella device (occluder) has no evident interface of the sub-layers specific for a deposited layer.

EFFECT: umbrella device with the modified coating layer possesses biocompatibility, corrosive resistance and no toxicity.

9 cl, 2 dwg

FIELD: metallurgy.

SUBSTANCE: initial components represent SiO2 or titaniferous magnetite and SiO2 to be mixed with carbonate Li(Li2CO3) at the ratio of 55-70 mol. % initial components, Li2CO3 and FeCO3 making the rest in equal amounts of cathode materials LixFeyMzSiO4/C. Then, powder is fused at 1180±5°C. After cooling, obtained alloy is ground to introduce therein, as high-molecular compound, polymethyl methacrylate or soot in amount of 2-5% of alloy. Then, thermal treatment is performed in cycling mode. For this it is heated to ≥600°C and held for 55-65 minutes. Now, it is cooled to room temperature in 5-10 cycles along with powder surface modification by carbon at heating.

EFFECT: storage battery higher discharge capacity.

5 dwg, 8 ex

FIELD: chemistry.

SUBSTANCE: membrane is made of a tetrafluoroethylene copolymer with functional perfluorinated comonomers of the general structural formula: where R: (D), (E), (K), M-H, Li, K, Na; a=24.75-18.38 mol.%; b=78.62-81.12 mol.%; c=5.0-0.5 mol.%; and is from 10 mcm and higher thick, density is 1.93-2.10 g/cm3, mechanical strength is 16-22 MPa and a coefficient of gas permeability by hydrogen (K) is 1-3.7×10-16 m3m m-2Pa-1s-1 at 20-90°C. A method of obtaining consists in combination of a porous polytetrafluoroethylene film with a perfluorosulphocationite polymer in a medium of an organic or a water-organic solvent in the presence of a modifier. The modifier is represented by hydrocarbon polymers, fluoropolymers, perfluoropolymers or their mixtures, inorganic compounds or their mixtures.

EFFECT: high drops of pressure, high current density and efficiency of an electrolysis cell exploitation.

13 cl, 3 tbl, 28 ex

FIELD: chemistry.

SUBSTANCE: asphalt-concrete mixture containing oil viscous bitumen, a filling agent, sand with fraction to 5 mm, crushed stone and an additive contains as crushed stone crushed granite with fraction 5-15 mm, as sand - sweepings of rock crushing, as the filling agent - sludge of HES water preparation and as the additive - a homogeneous short-fibre cellulose fibre and an organomineral modifier, containing sludge of HES water preparation, Portland cement, a polymer additive Butonal NS 198 and sodium pyrophosphate, with the following component ratio, wt %: oil viscous bitumen 6.3-6.9, crushed granite with fraction 5-15 mm 62.8-67.5, sweepings of rock crushing with fraction 0-5 mm 13.5-17.6, homogeneous short-fibre cellulose fibre 0.2, filling agent - sludge of HES water preparation 12.47-12.48, sludge of HES water preparation 0.0158-0.0238, Portland cement 0.0016-0.00235, polymer additive Butonal NS 198 0.0024-0.00357, sodium pyrophosphate 0.0002-0.00028.

EFFECT: increased water resistance of asphalt-concrete mixtures.

2 tbl

FIELD: medicine.

SUBSTANCE: material consists of several layers: an inner layer is made from chitosan nanofibres/superfine fibres, and an outside layer are used as an electrical forming substrate and exercise the protective function. The chitosan layer is made from herbal or mixed herbal and animal chitosan and can contain antibiotic. The multilayer material can contain at least one more layer of biopolymer nanofibres/superfine fibres electroformed of cellulose diacetate or gelatin. The three-layer material with the chitosan layer of the nanofibres/superfine fibres is applicable for local wound and burn healing.

EFFECT: material resistance to mechanical stress.

15 cl, 4 dwg, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of modifying envelopes of polyelectrolyte capsules with magnetite nanoparticles. The disclosed method involves producing a container matrix in form of porous calcium carbonate microparticles, forming envelopes of polyelectrolyte capsules by successive adsorption of polyallyl amine and polystyrene sulphonate and modifying with magnetite nanoparticles on the surface of the container matrix or after dissolving the matrix through synthesis of magnetite nanoparticles via chemical condensation.

EFFECT: invention enables to obtain modified polyelectrolyte capsules, designed to deliver medicinal substances which do not harm the human body.

3 cl, 4 dwg, 1 ex

Magnetic materials // 2244971

FIELD: magnetic materials whose axial symmetry is used for imparting magnetic properties to materials.

SUBSTANCE: memory element has nanomagnetic materials whose axial symmetry is chosen to obtain high residual magnetic induction and respective coercive force. This enlarges body of information stored on information media.

EFFECT: enhanced speed of nonvolatile memory integrated circuits for computers of low power requirement.

4 cl, 8 dwg